anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 220,771-220,800
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

220,771-220,800 of 303,780

filter-aware
09
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a cartoon liver character at the bottom.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a footer citing FDA approval precedents for similar patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
12
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a two-column layout to track progress for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
16
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
19
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
Includes detailed source citations and disclaimer regarding cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
The chart demonstrates deepening clinical responses over time, with sCR/CR increasing from 50% to 83%.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
25
The table highlights clinical safety data for NXC-201, showing low incidence of severe adverse events.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a footer citing FDA approval precedents for patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses bar charts to compare IMX-110 performance against standard drugs like Trabectedin and a 4-drug combination.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
Includes waterfall charts and longitudinal patient response plots; highlights PFS (progression-free survival) and line of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The slide uses a process flow diagram to show the progression of clinical trials for two different treatment regimens.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
Includes two sets of charts: tumor volume line graphs and survival curves. References specific study methodology in footnotes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
The slide uses a two-part structure: clinical efficacy (top right) and mechanism of action (bottom right).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit